Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pomalidomide plus low‑dose dexamethasone in refractory or relapsed and refractory multiple myeloma
2012-001888-78Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Aug 2012
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pomalidomide in multiple myeloma (MM), sponsored by Celgene Corporation. Primary endpoint: Safety and tolerability of pomalidomide + low-dose dexamethasone. Started Aug 2012; status: completed.
02
Drugs
pomalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2012-001888-78.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001888-78.